Skip to main content
Egyptian Rheumatology and Rehabilitation

Table 2 stratifying individual patient risk: pre-pregnancy counselling: assessment of the lupus nephritis risks and laboratory investigations

From: Egyptian recommendations for treating to target of lupus nephritis: an evidence-based consensus on clinical practice recommendations for the management of lupus nephritis and pregnancy

Risk assessment

Laboratory investigations

- Assessment of SLE disease activity

- Assessment of kidney function status as well as major organ involvement

- hypercoagulability status

- Concurrent medical disorders that may impact pregnancy.

- Previous obstetric outcomes should be reviewed

- Attention should be paid to history of small for gestational age foetus, preeclampsia, stillbirth, miscarriage, and preterm birth.

- Anti-Ro/SSA and anti-La/SSB antibodies

- Renal function (creatinine, urinalysis with urine sediment, spot urine protein/creatinine ratio, 24-hour urine protein)

- Complete blood count (CBC)

- Liver function tests

- Anti-double-stranded DNA (dsDNA) antibodies

- Complement (CH50, or C3 and C4)

- aPLs (lupus anticoagulant [LA], immunoglobulin G [IgG] and IgM anticardiolipin [aCL] antibodies, and IgG and IgM anti-beta2-glycoprotein [GP] I antibodies).

  1. dsDNA anti-double-stranded DNA, aPL anti-phospholipid antibodies, C3 complement, CBC complete blood count, dsDNA anti-double-stranded DNA, LA lupus anticoagulant, IgG immunoglobulin G, aCL anticardiolipin antibodies, GP anti-beta2-glycoprotein
Back to article page